XML 43 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statement of Equity (USD $)
Total
Parent Company
BIOMED REALTY, L.P.
Common Stock
Parent Company
Additional Paid-In Capital
Parent Company
Accumulated Other Comprehensive (Loss)/Income
Parent Company
Accumulated Other Comprehensive (Loss)/Income
BIOMED REALTY, L.P.
Dividends in Excess of Earnings
Parent Company
Total Stockholders'/Partner's Equity
Parent Company
Total Stockholders'/Partner's Equity
BIOMED REALTY, L.P.
Noncontrolling Interest
Parent Company
Noncontrolling Interest
BIOMED REALTY, L.P.
Limited Partner
Common Stock
BIOMED REALTY, L.P.
General Partner [Member]
Common Stock
BIOMED REALTY, L.P.
Forward Starting Swaps
BIOMED REALTY, L.P.
Interest Rate Swaps
BIOMED REALTY, L.P.
Balance - value - period start at Dec. 31, 2013   $ 2,987,025,000 $ 2,987,025,000 $ 1,921,000 $ 3,554,558,000 $ (32,923,000) $ (30,663,000) $ (583,569,000) $ 2,939,987,000 $ 2,985,695,000 $ 47,038,000 $ 1,330,000 $ 45,708,000 $ 2,970,650,000    
Balance - units - period start at Dec. 31, 2013                         5,415,974 192,115,002    
Balance - shares - period start at Dec. 31, 2013       192,115,002                        
Stock Issued During Period, Value, New Issues   (49,000) (49,000)   (49,000)       (49,000) (49,000)       (49,000)    
Net issuances of unvested restricted common stock/OP units - shares       400,264                   400,264    
Net issuances of unvested restricted common stock/OP units - value   (3,782,000) (3,782,000) 4,000 (3,786,000)       (3,782,000) (3,782,000)       (3,782,000)    
Conversion of OP units to common stock - shares       (10,500)                 (10,500) (10,500)    
Conversion of OP units to common stock - value         (51,000)       (51,000)   51,000   51,000 (51,000)    
Vesting of share-based awards   7,479,000 7,479,000   7,479,000       7,479,000 7,479,000       7,479,000    
Reallocation of equity to noncontrolling interests/limited partners         (265,000)       (265,000)   265,000   508,000 (508,000)    
Common stock dividends   (96,260,000)           (96,260,000) (96,260,000)              
OP unit distributions   (2,702,000) (98,962,000)             (98,962,000) (2,702,000)   (2,702,000) (96,260,000)    
Noncontrolling Interest, Increase from Business Combination   9,944,000 9,944,000               9,944,000 9,944,000        
Net income / (loss) (278,000) 39,865,000 39,865,000         37,469,000 37,469,000 38,504,000 2,396,000 1,361,000 1,035,000 37,469,000    
Other Comprehensive Income (Loss), Foreign currency translation adjustment   988,000 988,000     962,000 988,000   962,000 988,000 26,000          
Marketable Securities, Realized Gain (Loss)   (9,322,000) (9,322,000)     (7,784,000) (7,784,000)   (7,784,000) (7,784,000) (1,538,000) (1,538,000)        
Unrealized loss on equity securities   16,750,000 16,750,000     13,265,000 13,417,000   13,265,000 13,417,000 3,485,000 3,333,000        
Amortization of deferred interest costs   3,375,000       3,285,000 3,375,000   3,285,000 3,375,000 90,000       3,375,000  
Unrealized gain on derivative instruments, net   (918,000) (918,000)     (893,000) (918,000)   (893,000) (918,000) (25,000)         (918,000)
Balance - value - period end at Jun. 30, 2014   2,952,393,000 2,952,393,000 1,925,000 3,557,886,000 (24,088,000) (21,585,000) (642,360,000) 2,893,363,000 2,937,963,000 59,030,000 14,430,000 44,600,000 2,914,948,000    
Balance - units - period end at Jun. 30, 2014                         5,405,474 192,525,766    
Balance - shares - period end at Jun. 30, 2014       192,525,766                        
Balance - value - period start at Mar. 31, 2014                                
Net income / (loss)   19,098,000 19,098,000                          
Other Comprehensive Income (Loss), Foreign currency translation adjustment   750,000 750,000                          
Unrealized gain on derivative instruments, net   (328,000) (328,000)                          
Balance - value - period end at Jun. 30, 2014   $ 2,952,393,000 $ 2,952,393,000